Saturday 17 October 2026
Export MASS’s income statement to Excel — free account
908 Devices Inc.
MASS Healthcare Medical Devices
In the quarter to June 2026, revenue grew 23.3%, EPS grew 13.5% and free cash flow grew 151.0%, each against the same quarter a year earlier.
11.33
0.56
−4.71%
Follow MASS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 9.38 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.40 | 3.90 | 3.35 | 5.95 | |
P/FCF ratio |
533.71 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
103.51 | 187.00 | 142.89 | (75.22) | |
P/B ratio |
2.59 | 1.68 | 1.31 | 2.32 | |
Price to Tangible BV |
4.65 | 2.29 | 1.76 | 3.19 | |
EV/Sales |
3.98 | 2.23 | 1.62 | 4.13 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
162.44 | (17.30) | (3.84) | (8.06) | |
EV/FCF |
393.83 | (15.55) | (3.69) | (7.74) | |
Quick Ratio |
2.29 | 3.07 | 3.65 | 2.97 | |
Current Ratio |
2.67 | 3.58 | 4.24 | 3.49 | |
Net Debt/EBITDA |
8.92 | 9.66 | (26.87) | 7.23 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.31 | 0.30 | 0.32 | 0.29 | |
Operating CF/Net income |
(0.27) | (0.10) | 0.32 | 0.28 | |
Capex/Depreciation |
(0.11) | (0.03) | 0.01 | (0.81) | |
Research and Development Expense of Revenue |
22.38% | 25.94% | 20.16% | 27.40% | |
Selling, General and Administrative Expense of Revenue |
69.13% | 74.09% | 50.74% | 65.22% | |
Intangible Assets out of Total Assets |
0.28 | 0.19 | 0.19 | 0.19 | |
Share Based Compensation of Revenue |
14.39% | 17.93% | 15.91% | 16.99% | |
Graham Net Nets |
0.19 | 0.40 | 0.52 | 0.29 | |
Graham Number |
0.00 | 0.00 | 7.10 | 0.00 | |
Earnings Yield |
(10.80%) | (16.18%) | 10.67% | (1.26%) | |
Free Cash Flow Yield |
0.19% | (3.68%) | (13.08%) | (8.98%) | |
Revenue per Share |
0.43 | 0.36 | 0.48 | 0.39 | |
Operating CF per Share |
0.08 | 0.03 | 0.04 | (0.12) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
0.08 | 0.03 | 0.04 | (0.14) | |
Cash per Share |
2.69 | 3.03 | 3.15 | 3.10 | |
Shareholders Equity per Share |
3.36 | 3.64 | 4.00 | 3.78 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.36 | 3.64 | 4.00 | 3.78 | |
Free Cash Flow |
3.01 | 1.17 | 1.33 | (4.88) | |
Working Capital |
82.60 | 102.35 | 110.50 | 103.46 | |
Capital Expenditures |
(0.16) | (0.04) | 0.01 | (0.68) | |
Net Current Asset Value |
61.25 | 89.49 | 98.19 | 90.36 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.96 | 8.40 | 10.09 | 13.83 | |
Average Payables |
3.15 | 3.13 | 1.48 | 1.85 | |
Average Inventory |
14.92 | 12.99 | 11.94 | 16.58 | |
Average Assets |
194.62 | 191.36 | 174.77 | 184.58 | |
Average Common Equity |
137.79 | 146.80 | 129.15 | 133.67 |
Columns are period end dates